Logo
L

Lucid Diagnostics

100 employees

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device.

Investor insights

Funding rounds participated in

$15M sweet spot round size

Investor type

Public Company

Basic info

Industry

Medical Equipment Manufacturing

Sectors

Medical Equipment Manufacturing

Date founded

2018

Funding rounds raised

Total raised

$15M

from investors over 1 rounds

L

Lucid Diagnostics raised $15M on April 4, 2025

FAQ